Vaccinex: Up on opening clinical sites for antibody trial in cancer, Alzheimer's disease
08/06/2021 12:56
** Biotech co's shares VCNX.O rise 7% to $3.21 premarket
** Co says first clinical sites activated to screen and
enroll patients in an early-to-mid-stage studies of its novel
monoclonal antibody pepinemab in Alzheimer's disease and cancer
urn:newsml:reuters.com:*:nGNX8gFzFp
** Says early-stage study to look at pepinemab as a single
agent treatment for Alzheimer's disease, while a mid-stage study
will look at pepinemab in combination with Merck's MRK.N
Keytruda as front-line treatment for advanced, recurrent or
metastatic head and neck squamous cell carcinoma (HNSCC)
** Co says it plans to activate at least 13 U.S. sites for
the Alzheimer's study and 18 U.S. sites for HNSCC
** Up to last close, VCNX stock up about 45% YTD
(Reporting by Vishwadha Chander in Bengaluru)
((Vishwadha.Chander@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease